More than the years, many in vitro and in vivo studies have shown the antineoplastic effects of cannabinoids (CBDs), with reports advocating for investigations of mixture therapy approaches that could greater leverage these effects in clinical translation. This study explores the possible of mixture approaches employing CBDs with radiotherapy (RT) or wise biomaterials toward enhancing therapeutic efficacy in the course of therapy of pancreatic and lung cancers. In in vitro studies, clonogenic assay benefits showed higher productive tumor cell killing, when combining CBDs and RT. Meanwhile, in vivo study benefits revealed important boost in survival when employing wise biomaterials for sustained delivery of CBDs to tumor cells. The significance of these findings, considerations for additional study, and viable roadmap to clinical translation are discussed.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 29740535 PMCID: PMC5928848 DOI: 10.3389/fonc.2018.00114
Yasmin-Karim S1,two,three, Moreau Mtwo,three,four, Mueller R1,two,five, Sinha N1,two, Dabney Rsix, Herman Asix, Ngwa W1,two,three,four.